Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF, Aleixo SB, Rozas AA, Nunes de Matos Neto J, Caleffi M, Figueira AC, Souza SC, Reiriz AB, Gutierrez C, Arantes H, Uttenreuther-Fischer MM, Solca F, Osborne CK. Rimawi MF, et al. Among authors: solca f. Clin Breast Cancer. 2015 Apr;15(2):101-9. doi: 10.1016/j.clbc.2014.11.004. Epub 2014 Nov 15. Clin Breast Cancer. 2015. PMID: 25537159 Clinical Trial.
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J. Suder A, et al. Among authors: solca f. Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18. Eur J Cancer. 2015. PMID: 26296295 Clinical Trial.
Afatinib is active in osteosarcoma in osteosarcoma cell lines.
Cruz-Ramos M, Zamudio-Cuevas Y, Medina-Luna D, Martínez-Flores K, Martínez-Nava G, Fernández-Torres J, López-Reyes A, Solca F. Cruz-Ramos M, et al. Among authors: solca f. J Cancer Res Clin Oncol. 2020 Jul;146(7):1693-1700. doi: 10.1007/s00432-020-03220-y. Epub 2020 Apr 24. J Cancer Res Clin Oncol. 2020. PMID: 32333142
Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.
Varlet P, Bouffet E, Casanova M, Giangaspero F, Antonelli M, Hargrave D, Ladenstein R, Pearson A, Hawkins C, König FB, Rüschoff J, Schmauch C, Bühnemann C, Garin-Chesa P, Schweifer N, Uttenreuther-Fischer M, Gibson N, Ittrich C, Krämer N, Solca F, Stolze B, Geoerger B. Varlet P, et al. Among authors: solca f. Pediatr Blood Cancer. 2022 Jan;69(1):e29316. doi: 10.1002/pbc.29316. Epub 2021 Sep 21. Pediatr Blood Cancer. 2022. PMID: 34546642
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.
Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ. Slobbe P, et al. Among authors: solca f. Nucl Med Biol. 2014 Oct;41(9):749-57. doi: 10.1016/j.nucmedbio.2014.06.005. Epub 2014 Jun 25. Nucl Med Biol. 2014. PMID: 25066021
123 results